Advertisement

Topics

IPO Roundup: Allogene IPO prices above high end of range, Livent pricing comes up short, while Audentes Therapeutics debuts

07:00 EDT 11 Oct 2018 | Proactive Investors

Allogene Therapeutics Inc raised $288 million by offering 18.4 million shares, putting a spotlight on the biotech IPO boom this year

Original Article: IPO Roundup: Allogene IPO prices above high end of range, Livent pricing comes up short, while Audentes Therapeutics debuts

NEXT ARTICLE

More From BioPortfolio on "IPO Roundup: Allogene IPO prices above high end of range, Livent pricing comes up short, while Audentes Therapeutics debuts"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...